Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

- Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD -

GlobeNewsWire • Feb 22, 2026

Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors

BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a highly accomplished executive with a strong background in medicine and over 35 years of strategic experience in the biopharmaceutical industry.

GlobeNewsWire • Feb 2, 2026

Dyne Therapeutics: 2026 Catalysts Point To Further Upside

Dyne Therapeutics leverages its FORCE platform to target genetically driven muscle diseases with two lead clinical programs approaching pivotal milestones. DYNE-101 shows strong safety and functional improvement in DM1, with a potential BLA submission in Q3 2027 but faces competition and a lengthy timeline. DYNE-251's efficacy in DMD lags behind Avidity on a numerical basis, with a narrow therapeutic window and safety concerns at higher doses.

Seeking Alpha • Jan 27, 2026

Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?

Keros Therapeutics KROS is a clinical-stage biopharmaceutical company developing innovative therapies for patients with disorders caused by abnormal signaling within the transforming growth factor-beta (TGF-β) protein family.

Zacks Investment Research • Jan 27, 2026

Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1

- Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE Registrational Expansion Cohort in early Q2 2026 - WALTHAM, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug designation for zeleciment basivarsen (z-basivarsen), for the treatment of myotonic muscular dystrophy type 1 (DM1).

GlobeNewsWire • Jan 20, 2026

Dyne Therapeutics, Inc. (DYN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Dyne Therapeutics, Inc. (DYN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET).

GlobeNewsWire • Jan 7, 2026

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current chief executive officer of Collegium Pharmaceutical and having spent nearly a decade leading several lines of business and functions at Horizon Therapeutics.

GlobeNewsWire • Dec 23, 2025

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,827,549 shares of its common stock at a public offering price of $18.44 per share, which includes 2,847,071 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $402.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne. All of the shares in the offering were sold by Dyne.

GlobeNewsWire • Dec 11, 2025

Why Dyne Therapeutics Stock Was a Big Winner on Wednesday

An analyst upgraded his recommendation on the biotech. He now feels it's worthy of a buy, and what's more, he almost quadrupled his price target.

The Motley Fool • Dec 10, 2025